Orthocell Limited announced the appointment of The Hon Kim Beazley AC, as an Independent Non-Executive Director to the Board. Kim Beazley is a former Australian politician and diplomat, serving as a Minister in the Hawke and Keating Labor Governments holding the portfolios of Defence, Finance and Special Minister of State, among others. Mr. Beazley has also served as Deputy Prime Minister, Leader of the Australian Labor Party and Leader of the Opposition and, during his time in office, on parliamentary committees covering Intelligence, Foreign Affairs, Defence and Trade.

He was appointed a Companion of the Order of Australia in 2009 for service to the Parliament of Australia and was appointed the 33rd Governor of Western Australian in 2018, serving in this role until 2022. Mr. Beazley served as Ambassador to the United States of America between 2010 and 2016 and therefore brings a wealth of experience in matters of strategic engagement and advocacy in the US. In representing Orthocell, his experience will greatly support the Company's global commercial growth ambitions.

He currently holds advisory or consulting roles in the fields of business, technology, defence and policy. His commercial service currently extends to Chair of the Perth US Asia Centre Board; Board Member of Luerssen Australia; Senior Distinguished Fellow of the Australian Strategic Policy Institute; Adviser to Lockheed Martin Australia; Chair of the Council for the Australian War Memorial; and Adviser to TG & Associates. The appointment of Mr. Beazley is part of an exciting chapter of new leadership at the Board level, as Orthocell executes its global commercialisation and revenue growth plan for its world-class regenerative medicine product portfolio.

This news follows the appointment last year of experienced Independent Chairman, Mr. John Van Der Wielen, and another highly credentialed Independent Non-Executive Director, Professor Fiona Wood AM. With an experienced Board and Management Team, market leading products and strong balance sheet, Orthocell is well positioned to grow product sales alongside its distribution partners, BioHorizons and Device Technologies - which includes, as a priority, executing its US market access program and commercialisation strategy for its breakthrough nerve repair medical device, Remplir. Following Kim's appointment, the Orthocell Board has six Directors comprising five Non-Executive Directors and one Executive Director.

The aforementioned Board change will be effective 15 January 2024.